
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11142748/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	4.9	3,755
2	Dementia with Lewy bodies. Lancet Neurology, The, 2004, 3, 19-28.	4.9	645
3	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	13.9	626
4	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, The, 2007, 6, 305-313.	4.9	598
5	Diagnostic Criteria for Vascular Cognitive Disorders. Alzheimer Disease and Associated Disorders, 2014, 28, 206-218.	0.6	529
6	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 403-411.	6.3	444
7	Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability – The LADIS Study: Rationale, Design and Methodology. Neuroepidemiology, 2005, 24, 51-62.	1.1	387
8	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ: British Medical Journal, 2009, 339, b2477-b2477.	2.4	348
9	2001–2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?. Cerebrovascular Diseases, 2011, 32, 577-588.	0.8	258
10	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.4	246
11	A Magnetic Resonance Imaging Study of White Matter Lesions in Depression and Alzheimer's Disease. British Journal of Psychiatry, 1996, 168, 477-485.	1.7	215
12	Systematic Review and Meta-Analysis Show that Dementia with Lewy Bodies Is a Visual-Perceptual and Attentional-Executive Dementia. Dementia and Geriatric Cognitive Disorders, 2003, 16, 229-237.	0.7	206
13	Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ: British Medical Journal, 1998, 317, 982-984.	2.4	192
14	Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes. Archives of Internal Medicine, 2007, 167, 81.	4.3	187
15	Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease. Archives of Neurology, 2001, 58, 977.	4.9	167
16	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study. Cerebrovascular Diseases, 2009, 27, 384-391.	0.8	167
17	Age, Hypertension, and Lacunar Stroke Are the Major Determinants of the Severity of Age-Related White Matter Changes. Cerebrovascular Diseases, 2006, 21, 315-322.	0.8	164
18	Vascular basis of late-onset depressive disorder. British Journal of Psychiatry, 2002, 180, 157-160.	1.7	158

#	Article	IF	CITATIONS
19	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.4	143
20	Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1325-1330.	0.9	136
21	Is late onset depression a prodrome to dementia?. International Journal of Geriatric Psychiatry, 2002, 17, 997-1005.	1.3	132
22	Naltrexone as an Adjunctive Treatment for Older Patients With Alcohol Dependence. American Journal of Geriatric Psychiatry, 1997, 5, 324-332.	0.6	127
23	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	1.3	126
24	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurology, The, 2015, 14, 1171-1181.	4.9	124
25	Tackling challenges in care of Alzheimer's disease and other dementias amid the COVIDâ€19 pandemic, now and in the future. Alzheimer's and Dementia, 2020, 16, 1571-1581.	0.4	122
26	White Matter Hyperintensities Are Associated With Impairment of Memory, Attention, and Global Cognitive Performance in Older Stroke Patients. Stroke, 2004, 35, 1270-1275.	1.0	118
27	Global Burden of Small Vessel Disease–Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke, 2020, 51, 170-178.	1.0	115
28	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease. JAMA Neurology, 2020, 77, 164.	4.5	113
29	Guidelines for the management of agitation in dementia. International Journal of Geriatric Psychiatry, 2001, 16, 714-717.	1.3	101
30	Drug repositioning and repurposing for Alzheimer disease. Nature Reviews Neurology, 2020, 16, 661-673.	4.9	97
31	Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities. Age and Ageing, 2020, 49, 901-906.	0.7	94
32	fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. NeuroImage: Clinical, 2014, 4, 558-565.	1.4	93
33	Leukoaraiosis Predicts Hidden Global Functioning Impairment in Nondisabled Older People: The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Journal of the American Geriatrics Society, 2006, 54, 1095-1101.	1.3	83
34	METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimer's and Dementia, 2016, 12, 1235-1249.	0.4	82
35	Urinary Complaints in Nondisabled Elderly People with Ageâ€Related White Matter Changes: The Leukoaraiosis And DISability (LADIS) Study. Journal of the American Geriatrics Society, 2008, 56, 1638-1643.	1.3	81
36	MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. Cerebrovascular Diseases, 2009, 27, 336-344.	0.8	78

#	Article	IF	CITATIONS
37	The Association between White Matter Lesions on Magnetic Resonance Imaging and Noncognitive Symptoms. Annals of the New York Academy of Sciences, 2000, 903, 482-489.	1.8	77
38	Dementia: assessment, management and support: summary of updated NICE guidance. BMJ: British Medical Journal, 2018, 361, k2438.	2.4	77
39	Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). American Journal of Geriatric Psychiatry, 2009, 17, 726-733.	0.6	73
40	Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia. Annals of the New York Academy of Sciences, 2000, 903, 442-445.	1.8	69
41	Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data. Neuroepidemiology, 2006, 27, 101-116.	1.1	67
42	Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study. Cerebrovascular Diseases, 2013, 35, 544-553.	0.8	65
43	Synaptic Loss in Primary Tauopathies Revealed by [<scp>¹¹C</scp>] <scp>UCBâ€J</scp> Positron Emission Tomography. Movement Disorders, 2020, 35, 1834-1842.	2.2	61
44	Differential Atrophy of Hippocampal Subfields: A Comparative Study of Dementia with Lewy Bodies and Alzheimer Disease. American Journal of Geriatric Psychiatry, 2016, 24, 136-143.	0.6	55
45	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 85.	3.0	52
46	The characterisation and impact of ?fluctuating? cognition in dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2001, 16, 494-498.	1.3	49
47	Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. Ageing Research Reviews, 2017, 35, 250-264.	5.0	48
48	Structural Neuroimaging Studies in Late-Life Depression: A Review. World Journal of Biological Psychiatry, 2001, 2, 83-88.	1.3	47
49	How do memory clinics compare with traditional old age psychiatry services?. International Journal of Geriatric Psychiatry, 2001, 16, 837-845.	1.3	47
50	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT. Trials, 2009, 10, 57.	0.7	44
51	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry, 2013, 202, 121-128.	1.7	43
52	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. International Journal of Geriatric Psychiatry, 2017, 32, 1280-1304.	1.3	39
53	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusionâ€weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the) Tj ETQq1	11097843	1 &ıs gBT /O∨
54	Support and information needs following a diagnosis of dementia with Lewy bodies. International Psychogeriatrics, 2016, 28, 495-501.	0.6	32

#	Article	IF	CITATIONS
55	Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. Cortex, 2017, 92, 8-18.	1.1	32
56	Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open, 2012, 2, e000380.	0.8	31
57	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 398, 1487-1497.	6.3	31
58	Behavioral Symptoms in Vascular Cognitive Impairment and Vascular Dementia. International Psychogeriatrics, 2003, 15, 133-138.	0.6	30
59	Dementia with Lewy Bodies. Australian and New Zealand Journal of Psychiatry, 1999, 33, 800-808.	1.3	28
60	Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies. Neurology, 2021, 96, e2801-e2811.	1.5	25
61	Neuropsychological Deficits in Older Stroke Patients. Annals of the New York Academy of Sciences, 2002, 977, 179-182.	1.8	21
62	Dementia associated with psychiatric disorders. International Psychogeriatrics, 2005, 17, S207-S221.	0.6	20
63	Assessment of need and practice for assistive technology and telecare for people with dementia—The ATTILA (Assistive Technology and Telecare to maintain Independent Living At home for people with) Tj ETQq1 420-430.	1 0.784314 1.8	rgBT_/Overloc
64	Does hippocampal atrophy on MRI predict cognitive decline? A prospective follow-up study. International Journal of Geriatric Psychiatry, 1997, 12, 1182-1188.	1.3	18
65	Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT. Health Technology Assessment, 2021, 25, 1-156.	1.3	18
66	Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. British Journal of Psychiatry, 2021, 218, 276-282.	1.7	18
67	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology, 2014, 261, 1160-1169.	1.8	16
68	Neuroimaging of Dementia with Lewy Bodies. Neuroimaging Clinics of North America, 2012, 22, 67-81.	0.5	15
69	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Research, 2014, 3, 108.	0.8	15
70	Tolerability of Naltrexone in Treating Older, Alcohol-Dependent Patients. American Journal on Addictions, 1997, 6, 266-270.	1.3	11
71	A Longitudinal Study of Plasma <scp>pTau181</scp> in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease. Movement Disorders, 2022, 37, 1495-1504.	2.2	11
72	Competencies and training of radiographers and technologists for PET/MR imaging - a study from the UK MR-PET network. European Journal of Hybrid Imaging, 2020, 4, 1.	0.6	10

#	Article	IF	CITATIONS
73	Olfactory impairment in mild cognitive impairment with Lewy bodies and Alzheimer's disease. International Psychogeriatrics, 2022, 34, 585-592.	0.6	10
74	Tolerability of Naltrexone in Treating Older, Alcohol-Dependent Patients. American Journal on Addictions, 1997, 6, 266-270.	1.3	9
75	Neuroimaging in dementia and depression. Advances in Psychiatric Treatment, 2000, 6, 109-119.	0.6	8
76	Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 269-278.	0.8	8
77	Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Journal of the Neurological Sciences, 2002, 203-204, 41-48.	0.3	7
78	Assessment of autonomic symptoms may assist with earlyÂidentification of mild cognitive impairment with LewyÂbodies. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	6
79	Lessons from a pilot and feasibility randomised trial in depression (Blood pressure Rapid Intensive) Tj ETQq1 1 0.7	'84314 rgl 0.5	BT /Overloci 5
80	Blood pressure and heart rate responses to orthostatic challenge and Valsalva manoeuvre in mild cognitive impairment with Lewy bodies. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	4
81	Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET. Frontiers in Aging Neuroscience, 2018, 10, 306.	1.7	2
82	The neuropsychology of dementia. The Journal of the British Menopause Society, 2000, 6, 147-153.	1.3	1